Skip directly to content

The 2018 Pipeline Report

pipeline_2018_cover_generic_vert_250x314.png

JULY 2018

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Written by Mike Frick, Bryn Gay, Annette Gaudino, Mark Harrington, Tim Horn, Richard Jefferys, Jeremiah Johnson, Erica Lessem, and Lindsay McKenna

Welcome to the 2018 Pipeline Report, Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

We've streamlined this year’s report to provide our scientific, policy, and advocacy partners with web-based snapshots of the most critical developments and research milestones over the past year, focused on the Pipeline Report’s popular table formats. Hyperlinks to trusted sources of peer-reviewed data, analyses, guidance documents, and clinical trial information are included in all sections.

While a comprehensive bound version of the 2018 Pipeline Report will not be published this year, two detailed stand-alone papers will be available in Amsterdam in conjunction with the International AIDS Conference (IAC): Mike Frick’s TB Prevention Pipeline Report, to be distributed at TB 2018, and Richard Jeffery’s Research Toward a Cure and Immune-Based Therapies Pipeline to be disseminated at IAC.

We intend for these pages to serve as living documents, to be updated regularly by TAG staff with news of registrational approvals, research and development discontinuations, new entries, and pertinent clinical trial data. And additional pages will be added later this summer and fall: Erica Lessem’s review of diagnostics and treatments in development for tuberculosis; a detailed summary of experimental antiretroviral-based modalities for the primary prevention of HIV, to be authored and distributed by Jeremiah Johnson at the HIV Research for Prevention (R4P) conference this October in Madrid; another review by Jeremiah detailing biomedical interventions in development for a variety of sexually transmitted infections; and an overview of research development geared towards improving the prevention, diagnosis, and treatment of TB in pregnancy by Lindsay McKenna.

Please keep your eyes on these pages for updated content and be sure to let us know your thoughts on this new format: communications@treatmentactiongroup.org